

# Integrin targeting fluorescent proteins: exploration of RGD insertion sites

**Citation for published version (APA):**

Sonntag, M., Schill, J., & Brunsveld, L. (2017). Integrin targeting fluorescent proteins: exploration of RGD insertion sites. *ChemBioChem*, 18(5), 441–443. Advance online publication. <https://doi.org/10.1002/cbic.201600514>

**DOI:**

[10.1002/cbic.201600514](https://doi.org/10.1002/cbic.201600514)

**Document status and date:**

Published: 02/03/2017

**Document Version:**

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

**Please check the document version of this publication:**

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.tue.nl/taverne](http://www.tue.nl/taverne)

**Take down policy**

If you believe that this document breaches copyright please contact us at:

[openaccess@tue.nl](mailto:openaccess@tue.nl)

providing details and we will investigate your claim.

# Integrin-Targeting Fluorescent Proteins: Exploration of RGD Insertion Sites

Michael H. Sonntag, Jurgen Schill, and Luc Brunsveld\*<sup>[a]</sup>

The potential of the fluorescent protein scaffold to control peptide sequence functionality is illustrated by an exploration of fluorescent proteins as novel probes for targeting integrins. A library of fluorescent mCitrine proteins with RGD motifs incorporated at several positions in loops within the protein main chain was generated and characterized. Amino acid mutations to RGD as well as RGD insertions were evaluated: both led to constructs with typical mCitrine fluorescent properties. Screening experiments against four human integrin receptors revealed two strong-binding constructs and two selective integrin binders. The effect of the site of RGD incorporation illustrates the importance of the protein scaffold on RGD sequence functionality, leading to fluorescent protein constructs with the potential for selective integrin targeting.

The integrin receptor is the major cell surface receptor responsible for cell–cell and cell–matrix interactions. It is a heteromeric glycoprotein in which each subunit contributes to the ligand binding site.<sup>[1,2]</sup> Dimeric members are generated by the combination of one 18  $\alpha$ - and one 8  $\beta$ -subunit in the 24 known mammalian integrins.<sup>[2]</sup> Each integrin has a specific role, as demonstrated by gene knock-out experiments in mice.<sup>[3,4]</sup> About half of the integrins bind their ligands with a key tripeptide sequence: arginine-glycine-aspartic acid (RGD).<sup>[2,5–7]</sup> The interaction between RGD-containing proteins and their specific integrin receptors regulates a diverse array of fundamental cellular functions, including cell adhesion, migration, differentiation, and signaling.<sup>[1,8]</sup> Disregulation of these processes is involved in osteoporosis, inflammation, and several types of cancer, thus making integrins an appealing target for anticancer therapy.<sup>[8,9]</sup> This has resulted in the synthesis of RGD mimics as antagonists, imaging probes, and cell-adhesion material.<sup>[1,10–13]</sup> The relatively low affinity and integrin selectivity of linear RGD sequences can be increased by rigidification strategies, such as the use of cyclic peptides.<sup>[1,14–16]</sup> The RGD se-

quence has also been inserted into protein loops for binding and uptake applications.<sup>[17,18]</sup>

Fluorescent proteins, available in a diverse range of spectral characteristics, are highly attractive for the visualization of biological molecules, functions, and processes.<sup>[19,20]</sup> A frequently used and brightly fluorescent variant is monomeric Citrine (mCitrine).<sup>[21]</sup> The  $\beta$ -barrel fold of fluorescent proteins, with the chromophore in the center, is highly stable and amenable to mutations to the  $\beta$ -strands and the connecting loops.<sup>[22–24]</sup> As a result, incorporation of peptide epitopes into fluorescent proteins has potential for developing probes for bioimaging applications.<sup>[25,26]</sup> Fluorescent proteins have many loops as possible insertion sites for RGD motifs. Potentially, the microenvironment of each loop induces a specific conformation of the RGD motif and thus could modulate the affinity and selectivity for several integrins. Here we explore the insertion of the RGD sequences GRGDS into a number of loops of mCitrine and at the termini (Figure 1). We expressed this set of mCitrine var-




Figure 1. GRGDS insertion sites in mCitrine (PDB ID:1YFP).<sup>[27]</sup>

[a] Dr. M. H. Sonntag, J. Schill, Prof. L. Brunsveld  
Laboratory of Chemical Biology and  
Institute of Complex Molecular Systems  
Department of Biomedical Engineering, Eindhoven University of Technology  
Den Dolech 2, 5612 AZ Eindhoven (The Netherlands)  
E-mail: l.brunsveld@tue.nl

Supporting information and the ORCID identification numbers for the authors of this article can be found under <http://dx.doi.org/10.1002/cbic.201600514>.

© 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

iants, and evaluated their expression yield and fluorescence. A simple ELISA-like integrin-binding screening protocol was developed and used to evaluate the integrin affinities and specificities of the mCitrine-RGD probes.

Two strategies were employed for introducing GRGDS at different positions in mCitrine. The amino acid sequence was either inserted into the mCitrine sequence, thus expanding the size of the loop, or replaced a five-residue loop stretch, thus retaining the size of the loop. Reported mCitrine mutation sites<sup>[22,23]</sup> were used to introduce the GRGDS sequences (Figure 1), with the aim of retaining the integrity of the  $\beta$ -barrel fold. The N and C termini were also tested for GRGDS incorpo-


Table 1. mCitrine-RGD protein constructs and characteristics.				
GRGDS position	Cloning <sup>[a]</sup>	Fluorescence <sup>[b]</sup>	ELISA signal intensity [a.u.]	
			$\alpha_v\beta_3$ <sup>[c]</sup>	$\alpha_v\beta_5$ <sup>[c]</sup>
none	+	398	0.058 ± 0.010	0.123 ± 0.003
<b>Inserted</b>				
N terminus	+	n.a.	0.137 ± 0.014	0.133 ± 0.008
49/50	+	445	0.238 ± 0.008	0.146 ± 0.006
78/79	+	342	0.098 ± 0.002	0.142 ± 0.006
116/117	+	425	0.332 ± 0.013	0.249 ± 0.009
134/135	+	n.a.	0.480 ± 0.050	0.136 ± 0.013
140/141	+	393	1.60 ± 0.05	0.98 ± 0.10
157/158	+	372	0.164 ± 0.002	0.142 ± 0.001
172/173	+	393	0.445 ± 0.024	0.180 ± 0.010
189/190	+	377	0.313 ± 0.008	0.195 ± 0.004
194/195	+	240	1.90 ± 0.04	0.789 ± 0.025
213/214	+	405	0.629 ± 0.054	0.135 ± 0.006
C terminus	+	392	0.057 ± 0.010	0.142 ± 0.005
<b>Exchanged</b>				
49/53	+	270	0.057 ± 0.010	0.158 ± 0.003
78/82	+	38	0.177 ± 0.006	0.483 ± 0.025
116/121	+	n.a.	0.124 ± 0.003	0.125 ± 0.003
135/138	+	n.a.	0.64 ± 0.04	0.207 ± 0.044
140/144	+	n.a.	0.63 ± 0.02	0.439 ± 0.014
156/160	+	479	0.244 ± 0.009	0.164 ± 0.010
171/174	+	392	0.244 ± 0.011	0.188 ± 0.030
190/194	-	n.d.	n.d.	n.d.
194/198	+	235	1.158 ± 0.019	0.69 ± 0.01
211/215	+	192	0.095 ± 0.005	0.128 ± 0.009

[a] +: successful; -: not successful. [b] Fluorescence intensity (arbitrary units):  $\lambda_{\text{ex}} = 515$  nm,  $\lambda_{\text{em}} = 528$  nm for 1  $\mu\text{M}$  mCitrine-RGD in PBS; n.a. not active; n.d. not determined. [c] ELISA signal intensity for two representative integrins. Values are mean  $\pm$  SD ( $n = 3$ ).

ration, as these are non-structured, exposed protein elements. Site-directed mutagenesis was used to insert the GRGDS-encoding sequence in the mCitrine gene. Except for the 190/194 (exchanged) construct, all designed DNA constructs were successfully obtained (Table 1). The constructs were expressed as soluble fusion proteins in *Escherichia coli*, with an N-terminal His-tag for purification and surface immobilization for integrin-binding studies. The expressed proteins were purified by nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography with stringent washing to obtain mCitrine-RGD constructs with high purity (Figure S1 in the Supporting Information). Protein yields were between 0.5 and 28 mg per liter of lysogeny broth, thus reflecting the influence of the RGD modifications on mCitrine expression level. Notably, good integrin-binding constructs (e.g., 140/141 and 194/195; vide infra) expressed with higher yields. The functional integrity of the new protein constructs was assessed by analysis of the fluorescence properties (Table 1). The majority of the proteins exhibited fluorescence intensities and emission maxima similar to those of unmodified mCitrine, thus confirming the tolerance to RGD-epitope introduction. Nonfluorescent protein constructs were obtained when five residues were exchanged for GRGDS in the amino acid region 116 to 144. Insertion in this region was only problematic for the 134/135 construct. These findings indicate that the loops in this region have an important, probably allosteric, role in maintaining chromophore integrity, so generally do allow insertion of additional amino acids.

A microtiter-plate-based integrin-binding assay was established to simply and rapidly evaluate the binding of the expressed fluorescent mCitrine-RGD proteins to a set of integrin receptors. The assay was similar to an indirect enzyme-linked immunosorbent assay (ELISA): integrin receptor was immobilized on a microtiter-plate, and bound mCitrine-RGD was detected by its N-terminal His-tag (goat anti-His primary antibody with secondary antibody conjugated to horseradish peroxidase; Figure S2). The assay was initially optimized by using the 140/141 mCitrine-RGD protein and non-RGD-containing mCitrine as a negative control. Optimal signal to background ratios were obtained when using 0.1% (w/v) milk powder (blocking reagent) and 1:1000 (primary) and 1:10 000 (secondary) antibody dilutions (Figure S3).

All mCitrine-RGD constructs, including nonfluorescent, were screened against four different human integrin receptors: the RGD binding  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$ , and  $\alpha_5\beta_1$  receptors and the non-RGD-binding  $\alpha_1\beta_1$  receptor (Figure 2 and Table 1). The screening



**Figure 2.** mCitrine-RGD variants binding to human integrin receptors  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$ ,  $\alpha_5\beta_1$ , and  $\alpha_1\beta_1$ . A) GRGDS sequence inserted at the indicated positions. B) GRGDS substituted for five amino acids at the indicated positions.

revealed clear position-dependent differences in integrin binding. The mCitrine constructs with an additionally integrated GRGDS motif in position 140/141 and 194/195 turned out to be, overall, the strongest binders. For the mCitrine constructs in which five amino acids were exchanged for GRGDS, position 194/198 led to the most potent overall binder. The 78/82-exchanged construct bound to all integrins tested. However, as the  $\alpha_1\beta_1$  integrin typically does not bind its ligand in an RGD-

dependent fashion, the binding of the 78/82 construct to this and the other integrins could result from nonspecific binding. Whereas integrin  $\alpha_v\beta_5$  and especially  $\alpha_v\beta_3$  showed relevant binding to a diverse set of protein constructs, integrins  $\alpha_5\beta_1$  and  $\alpha_1\beta_1$  basically showed no affinity for the mCitrine-RGD constructs. In general, integration of the GRGDS motif by insertion led to constructs with higher integrin binding than those generated by exchange. The enhanced binding of the mCitrine mutants with an inserted GRGDS motif is intriguing; it might be due, in part, to the better surface exposure of the RGD motif caused by having five extra amino acids in the protein sequence.

The importance of the structure of the GRGDS sequence for affinity is illustrated by the absence of binding by the two constructs with the RGD epitope in the flexible N or C terminus (0/1 and 240/241). Both nonfluorescent mutants at amino acid 135 (134/135 and 135/138), and the fluorescent constructs 213/214 and (to a lesser extent) 172/173 displayed selectivity for  $\alpha_v\beta_3$  over  $\alpha_v\beta_5$ . The local chemical environment of the loop thus confers binding selectivity.<sup>[28]</sup>

The two most prominent integrin-binding probes, those with insertions at 140/141 and 194/195, were analyzed for integrin-binding specificity. For this, GRGDS was substituted with GRADS. The single additional methylene group reduced the binding to all four integrins back to the mCitrine background levels (Figure S4), thus confirming the selective binding of the mCitrine-RGD constructs to  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$ . The constrained turns thus orient the side chains with respect to the peptide backbone; this determines binding specificity, as postulated by Kessler and colleagues.<sup>[8]</sup>

Fluorescent proteins are versatile tools in chemistry and biology, and incorporation of RGD motifs in the loops provides entry to genetically encoded fluorescent probes for integrins. Our library of 22 mCitrine-RGD constructs contained strong binders for  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  as well as integrin subtype-selective binders. Loop selection was essential, as shown by the inactivity in integrin binding by constructs with the RGD sequence in the flexible termini and in some other loops. The insertion of RGD motifs in mCitrine loops thus imposes a specific structure and microenvironment on the RGD motif; this can facilitate integrin binding and selectivity, and provides an intriguing platform for studies of the structure–function relationship of diverse RGD geometries. The strong-binding 140/141 and 194/195 constructs have GRGDS at opposite sites of the  $\beta$ -barrel (Figure 1). The activity and selectivity at these two different positions in mCitrine could be advantageous in homo- or heterodimeric sandwich systems, thereby allowing binding to the two sides of mCitrine for integrin targeting and imaging at the cellular level. Constrained peptide motifs enable tissue targeting.<sup>[5,8,9]</sup> The mCitrine scaffold also offers the possibility to insert other specific sequences (e.g., NGR<sup>[29]</sup> and YIGSR<sup>[30]</sup>) in combination with GRGDS. Such combinations provide access to specific targeting with fluorescent proteins.

## Acknowledgements

The research was supported by funding from NanoSci-E+ to the NanoActuate project through STW grant 11022-NanoActuate and by the Ministry of Education, Culture and Science (Gravity program 024.001.035).

**Keywords:** fluorescent probes • integrin • protein engineering • protein-protein interactions • RGD

- [1] E. Ruoslahti, *Annu. Rev. Cell Dev. Biol.* **1996**, *12*, 697–715.
- [2] R. O. Hynes, *Cell* **2002**, *110*, 673–687.
- [3] A. De Arcangelis, E. Georges-Labouesse, *Trends Genet.* **2000**, *16*, 389–395.
- [4] D. Sheppard, *Matrix Biol.* **2000**, *19*, 203–209.
- [5] M. D. Pierschbacher, E. Ruoslahti, *Nature* **1984**, *309*, 30–33.
- [6] M. D. Pierschbacher, E. Ruoslahti, *Proc. Natl. Acad. Sci. USA* **1984**, *81*, 5985–5988.
- [7] S. M. Albelda, C. A. Buck, *FASEB J.* **1990**, *4*, 2868–2880.
- [8] A. Meyer, J. Auernheimer, A. Modlinger, H. Kessler, *Curr. Pharm. Des.* **2006**, *12*, 2723–2747.
- [9] J. S. Desgroesellier, D. A. Cheresh, *Nat. Rev. Cancer* **2010**, *10*, 9–22.
- [10] U. Hersel, C. Dahmen, H. Kessler, *Biomaterials* **2003**, *24*, 4385–4415.
- [11] W. Alsibai, A. Hahnenkamp, M. Eisenblätter, B. Riemann, M. Schäfers, C. Bremer, G. Haufe, C. Hölte, *J. Med. Chem.* **2014**, *57*, 9971–9982.
- [12] D. Pallarola, A. Bochen, H. Boehm, F. Rechenmacher, T. R. Sobahi, J. P. Spatz, H. Kessler, *Adv. Funct. Mater.* **2014**, *24*, 943–956.
- [13] R. De Marco, A. Tolomelli, E. Juaristi, L. Gentilucci, *Med. Res. Rev.* **2016**, *36*, 389–424.
- [14] A. Hautanen, J. Gailit, D. M. Mann, E. Ruoslahti, *J. Biol. Chem.* **1989**, *264*, 1437–1442.
- [15] M. A. Dechantsreiter, E. Planker, B. Mathä, E. Lohof, G. Hölzemann, A. Jonczyk, S. L. Goodman, H. Kessler, *J. Med. Chem.* **1999**, *42*, 3033–3040.
- [16] R. Haubner, W. Schmitt, G. Hölzemann, S. L. Goodman, A. Jonczyk, H. Kessler, *J. Am. Chem. Soc.* **1996**, *118*, 7881–7891.
- [17] V. A. Manning, S. M. Hamilton, P. A. Karplus, L. M. Ciuffetti, *Mol. Plant-Microbe Interact.* **2008**, *21*, 315–325.
- [18] T. A. Khan, X. Wang, J. A. Maynard, *Biochemistry* **2016**, *55*, 2078–2090.
- [19] R. Y. Tsien, *Annu. Rev. Biochem.* **1998**, *67*, 509–544.
- [20] D. M. Chudakov, M. V. Matz, S. Lukyanov, K. A. Lukyanov, *Physiol. Rev.* **2010**, *90*, 1103–1163.
- [21] N. C. Shaner, P. A. Steinbach, R. Y. Tsien, *Nat. Methods* **2005**, *2*, 905–909.
- [22] M. R. Abedi, G. Caponigro, A. Kamb, *Nucleic Acids Res.* **1998**, *26*, 623–630.
- [23] G. S. Baird, D. A. Zacharias, R. Y. Tsien, *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 11241–11246.
- [24] T. Kadosono, E. Yabe, T. Furuta, A. Yamano, T. Tsubaki, T. Sekine, T. Kuchimaru, M. Sakurai, S. Kizaka-Kondoh, *PLoS ONE* **2014**, *9*, e103397.
- [25] T. V. Pavoov, Y. K. Cho, E. V. Shusta, *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 11895–11900.
- [26] S. Viswanathan, M. E. Williams, E. B. Bloss, T. J. Stasevich, C. M. Speer, A. Nern, B. D. Pfeiffer, B. M. Hooks, W.-P. Li, B. P. English, T. Tian, G. L. Henry, J. J. Macklin, R. Patel, C. R. Gerfen, X. Zhuang, Y. Wang, G. M. Rubin L. L. Looger, *Nat. Methods* **2015**, *12*, 568–576.
- [27] R. M. Wachter, M. A. Elsliger, K. Kallio, G. T. Hanson, S. J. Remington, *Structure* **1998**, *6*, 1267–1277.
- [28] M. Pfaff, K. Tangemann, B. Müller, M. Gurrath, G. Müller, H. Kessler, R. Timpl, J. Engel, *J. Biol. Chem.* **1994**, *269*, 20233–20238.
- [29] A. Corti, F. Curnis, W. Arap, R. Pasqualini, *Blood* **2008**, *112*, 2628–2635.
- [30] J. Graf, Y. Iwamoto, M. Sasaki, G. R. Martin, H. K. Kleinman, F. A. Robey, Y. Yamada, *Cell* **1987**, *48*, 989–996.

Manuscript received: September 19, 2016

Accepted Article published: December 22, 2016

Final Article published: January 27, 2017